Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…
To read the full story
Related Article
BUSINESS
- Novartis Files for Arbitration with ICC, Claiming No Obligation to Pay Certain Royalties for Fingolimod to Mitsubishi Tanabe
February 21, 2019
- Japan Pharma Market Down 1.7% in 2018, with Maviret as Top-Selling Product: IQVIA Data
February 21, 2019
- Janssen Files Protease Inhibitor/NRTIs Combo for HIV Infection in Japan
February 21, 2019
- Ono/Seikagaku’s Novel Osteoarthritis Drug Hits Primary Goal in Japan PIII
February 20, 2019
- EA Pharma Grabs Japan Rights to Dr. Falk’s Liver Therapy
February 20, 2019
A series of drug makers restructured or sold off production facilities in FY2018. Others dissolved or withdrew from the pharmaceutical business altogether. The entry of generics and transfer of products triggered these moves, but the underlying factor was the impact…
With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…